Results 61 to 70 of about 5,784 (166)

Vismodegib as Novel Treatment of Periocular Basal Cell Carcinoma: A Mini Review [PDF]

, 2020
Basal cell carcinoma (BCC) is the most common cancer in the world. This study aims to review vismodegib treatment in BCC patients. Vismodegib has been approved for the treatment of adults with mBCC, or with laBCC that has recurred after surgery or who ...
Hendrian Dwikoloso Soebagjo
core   +1 more source

Machine Learning Enables Rapid Prediction of Acid‐Reducing Agent Drug Interactions: A Streamlined Complement to PBPK Modeling

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
Machine Learning Enables Rapid Prediction of Acid‐Reducing Agent Drug Interactions: A Streamlined Complement to PBPK Modeling. ABSTRACT pH‐dependent drug–drug interactions (DDIs) commonly occur when acid‐reducing agents (ARAs) are co‐administered with weakly basic drugs.
Yuanfang Qin, Lehua Yu, Tao Chen, Yonghui Zuo, Hongyun Wang, Guoping Yang, Qi Pei   +6 more
wiley   +1 more source

Effekt von Vismodegib (Erivedge®) in Kopf-Hals-Tumoren

, 2015
Einleitung: Der reaktivierte Hedgehog-Signalweg (HhP) begünstigt die Tumorentstehung und vermittelt Resistenzmechanismen. Durch eigene Vorarbeiten konnte die Überexpression von Proteinen des HhP auch in Kopf-Hals-Tumoren (HNSCC) nachgewiesen werden. Mit
Günther, G, Dietz, A, Boehm, A, Mozet, C, Reiche, A, Liebig, H, Wichmann, G   +6 more
core   +1 more source

Keratin positive micro-tumors present despite complete clinical response to vismodegib.

, 2022
A) Pathology results for excision samples after vismodegib treatment (error bars indicate 95% CI, n = 9 (left column), n = 18 (right column)), B) Pre- and post-vismodegib histology, C) Average total area and D) Average lesion size (pixels) of keratin 5 ...
Shelby P. Unsworth (8748393), Christopher A. Andrews (14204716), May P. Chan (14204719), Alon Kahana (197271), Curtis J. Heisel (8748390), Emily A. Eton (14204713), Christina F. Tingle (8748387), Scott C. Bresler (14204722)   +7 more
core   +1 more source

The Gli Inhibitor More Effectively Down-regulated Gli Expression than Vismodegib. A

, 2013
, Immunofluorescence staining of Gli1 and Gli2 upon 48 hr treatment of Gli-I and vismodegib in three MPM cell lines. B, RT-PCR analysis of gli1 and gli2 expression upon 30 hr treatment of Gli-I and vismodegib.
Tiffany Cheng (385862), Dongsheng Yue (385864), Qing Sheng (50321), Joy Q. Jin (385867), Thomas W. Luh (385868), Natalie Lui (385861), Hsin-Hui K. Tseng (385863), David M. Jablons (154819), Etienne Giroux-Leprieur (385865), Hui Li (32376), Biao He (1833), Hanh T. Do (385866)   +11 more
core   +1 more source

Real-world experience with vismodegib and sonidegib in advanced basal cell carcinoma: a multicenter Italian study

Dermatology Reports
Vismodegib and sonidegib are smoothened (SMO) inhibitors approved for the treatment of advanced basal cell carcinoma (aBCC). This study investigates the real-world experiences and outcomes associated with these therapies across multiple Italian centers ...
Mario Valenti, Sara Di Giulio, Andrea Carugno, Pasquale Frascione, Angelo Valerio Marzano, Santo Raffaele Mercuri, Gianluca Nazzaro, Giulia Spallone, Giovanni Paolino, Marco Ardigò   +9 more
doaj   +1 more source

Sonidegib efficacy and safety in ultra‐nonagenarian patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Camilla Brunello, Andrea Corio, Marco Zanette, Raffaele Dante Caposiena Caro, Iris Zalaudek, Nicola di Meo   +5 more
wiley   +1 more source

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong, Lingshuang Wang, Hui Zhang, Menghuan Li, Zhong Luo, Yan Hu, Chunyuan Cai   +6 more
wiley   +1 more source

Reflectance Confocal Microscopy Identification of Subclinical Basal Cell Carcinoma after Vismodegib Treatment: Report of a Case

, 2021
Although surgery represents the treatment of choice for the majority of basal cell carcinomas, different therapies are required to treat the advanced ones.
Fabbrocini G., Villani A., Scalvenzi M., Costa C., Gabriella Fabbrocini, Claudia Costa, Alessia Villani, Massimiliano Scalvenzi   +7 more
core   +1 more source

Unveiling Candidate Markers for Drug Resistance or Synthetic Lethality in Cervical Cancer: Integrative Analysis of Genetic and Pharmacoprofiling

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Introduction Systemic cervical cancer management continues to be challenging. Numerous chemotherapies have been approved, but predicting response is difficult due to the lack of biomarkers. Here, we analyze the genetic and protein profiles of 20 cervical cancer cell lines (CCCLs) and explore their correlation with drug response patterns to ...
Suzy Scholl, Elaine Del Nery, Pierre Gestraud, Maral Halladjian, Elodie Girard, Adèle Soria, Elodie Anthony, Leanne De Koning, Nicolas Servant, Els Berns, Maud Kamal   +10 more
wiley   +1 more source